Mobile

A clinical study to evaluate the safety and benefit from using Everolimus and Exemestane in combination in postmenopausal women with estrogen receptor positive breast cancer

Update Il y a 4 ans
Reference: EUCTR2011-006111-62

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the Overall Response Rate (ORR) in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with NSAIs treated with the combination of Everolimus and Exemestane.

Inclusion criteria

  • The trial aims to evaluate the efficacy, safety, quality of life and health resources in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with NSAIs treated with the combination of Everolimus and Exemestane

Links